Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States ( SMILE )
Main finding · Incident cardiometabolic comorbidities (prediabetes or T2D, T2D only, hypertension, ASCVD, HF, CVD)Result — go to the resultHRs 0.45-0.75Authors' conclusion
Semaglutide 2.4 mg was associated with lower risk of multiple cardiometabolic comorbidities, favourable changes in biomarkers, and lower estimated ASCVD risk in this population.
Study context
- Population
- Adults with obesity or with overweight and ≥ 1 obesity-related comorbidity, Komodo Research Database (2016–2024)
- Participants
- 25,783 vs 8,948,913
- Exposure
- Semaglutide 2.4 mg vs non-users
- Semaglutide 2.4 mgn = 25,783
- Non-usersn = 8,948,913reference
- Outcome
- Incident cardiometabolic comorbidities (prediabetes or T2D, T2D only, hypertension, ASCVD, HF, CVD)
Methodological detailspropensity score weighting, US claims data
- Propensity score weighting
- US claims data
Main finding
As reported in the abstract
HRs
0.45-0.75
all p < 0.05
Observational data: associations, not effects.
Further findings
| Outcome | Semaglutide 2.4 mg | Non-users | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Proportion at intermediate-high ASCVD risk · 12 months | 14.9%-9.3% | 17.7%-18.7% | 0.3 (0.1–0.6) | P < 0.001 | |
| 0.10.31310Odds ratio (log scale) |
| Outcome | Semaglutide 2.4 mg | Non-users | Estimate | P value |
|---|---|---|---|---|
| Change in cardiometabolic biomarkers | BMI −4.1 kg/m² | all p < 0.001 | ||
| Change in cardiometabolic biomarkers | SBP −6.2 mmHg | all p < 0.001 | ||
| Change in cardiometabolic biomarkers | HbA1c −0.4 % | all p < 0.001 | ||
| Change in cardiometabolic biomarkers | LDL-C −7.7 mg/dL | all p < 0.001 | ||
| Change in cardiometabolic biomarkers | TG −28.6 mg/dL | all p < 0.001 | ||
| Change in cardiometabolic biomarkers | HDL-C +1.9 mg/dL | all p < 0.001 | ||
| Change in 10-year ASCVD risk score · 12 months | −0.7% | +0.3% | between-group difference −1.0 % | P < 0.001 |
- Change in 10-year ASCVD risk score: semaglutide users N = 161
Original publication
Semaglutide 2.4 mg Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States ( SMILE ). Diabetes Obes Metab. Published 27 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →